LETTER TO THE EDITOR
COVID-19 Cytokine Storm Complications in Asthmatic Patients
Entezar Mehrabi Nasab1, Seyyed Shamsadin Athari2, *
Article Information
Identifiers and Pagination:
Year: 2020Volume: 13
First Page: 625
Last Page: 626
Publisher ID: TOPHJ-13-625
DOI: 10.2174/1874944502013010625
Article History:
Received Date: 16/05/2020Revision Received Date: 09/09/2020
Acceptance Date: 12/09/2020
Electronic publication date: 13/11/2020
Collection year: 2020
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
The pandemic of coronavirus disease 2019 has inflicted millions of people in the world and caused severe complications in immunocompromised individuals. Some evidences suggest that severe COVID-19 complications are associated with the cytokine storm syndrome, contributing to the high mortality rate of the disease. Asthma is a complicated disease of the respiratory system. COVID-19 symptoms can be worse in asthmatic patients than others. Corticosteroids with anti-inflammatory functions which are used in asthmatic patients may have adverse outcomes in coronavirus infection and are not recommended for the treatment of COVID-19. Furthermore, asthmatic patients (using inhalation corticosteroids) have a suppressed immune system in the lung, which increases their susceptibility to COVID-19 infection.